Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck Launches HPV Awareness Campaign In Preparation For Gardasil

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The firm has launched television, radio and print ads although the HPV vaccine is still pending at FDA.

You may also be interested in...



Merck Launches "One Less" Gardasil DTC Ads Targeting Teens

Campaign for the cervical cancer vaccine includes print, broadcast and online ads.

Merck Launches "One Less" Gardasil DTC Ads Targeting Teens

Campaign for the cervical cancer vaccine includes print, broadcast and online ads.

Gardasil Efficacy In Patients Already Infected With HPV Will Be Addressed By Advisory Panel

Potential of strains not contained in Merck’s HPV vaccine to offset efficacy of Gardasil will also be discussed at the committee’s May 18 meeting.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

Pink Sheet Podcast: Alzheimer’s Drugs, US FDA’s New Patient Info Leaflet, COVID-19 Vaccine Harmonization

Why Generic Drug Manufacturing Is Faltering And Ways To Bolster It

See All
UsernamePublicRestriction

Register

PS064266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By